IGF1R-Targeted Therapy and Its Enhancement of Doxorubicin Chemosensitivity in Human Osteosarcoma Cell Lines

REFERENCES

• Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007;19:341–346.
   PubMed Web of Science ®Google Scholar
• de Saint Aubain Somerhausen N, Fletcher CDM. Soft-tissue sarcomas: an update. Eur J Surg Oncol 1999;25(2):215–220.
   PubMedGoogle Scholar
• Anderson PM. Effectivness of radiotherapy for osetosarcoma that responds to chemotherapy. Mayo Clin Proc 2003;78:145–146.
   PubMedGoogle Scholar
• Machak GN, TkachevSI, SolovyevYN, SinyukovPA, IvanovSM, KocherginaNV, RyjkovAD, TepliakovVV, BokhianBY, and GlebovskayaVV, Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma for extremities. Mayo Clin Proc 2003;78:147–155.
   PubMed Web of Science ®Google Scholar
• DeLaney TF, ParkL, GoldbergSI, HugEB, LiebschNJ, MunzenriderJE, and SuitHD, Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol 2005;61(2):492–498.
   PubMed Web of Science ®Google Scholar
• Casa AJ, DearthRK, LitzenburgerBC, LeeAV, and CuiX, The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Frontiers Biosci 2008;13:3273–3287.
   PubMed Web of Science ®Google Scholar
• Hartog H, WesselingJ, BoezenHM, and van der GraafWTA, The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007;43:1895–1904.
   PubMed Web of Science ®Google Scholar
• Chitnis MM, YuenJS, ProtheroeAS, PollakM, and MacaulayVM, The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14(20):6364–6370.
   PubMed Web of Science ®Google Scholar
• Paz K, Hadari YR. Targeted therapy of the insulin-like growth factor-1 receptor in cancer. Comb Chem High Throughput Screen 2008;11:62–69.
   PubMed Web of Science ®Google Scholar
• Miller B, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 2005;65(22): 10123–10127.
   PubMed Web of Science ®Google Scholar
• Rochester MA, RiedemannJ, HellawellGO, BrewsterSF, and MacaulayVM, Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005;12:90–100.
   PubMed Web of Science ®Google Scholar
• Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials—early lessons. J Mammary Gland Biol 2008;13: 471–483.
   PubMed Web of Science ®Google Scholar
• Párrizas M, GazitA, LevitzkiA, WertheimerE, and Le roith D, Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and bilogical function by tyrphostins. Endocrinology 1997;138(4):1427–1433.
   PubMed Web of Science ®Google Scholar
• Deutsch E, MaggiorellaL, WenB, BonnetML, KhanfirK, FrascognaV, TurhanAG, and BourhisJ, Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on ST1571-resistant Bcr-Abl expressing cells and decrease AKT phosphorylation. Br J Cancer 2004;91:1735–1741.
   PubMed Web of Science ®Google Scholar
• Wen B, DeutschE, FrasconaV, MaggiorellaL, AbdulkarimB, ChavaudraN, and BourhisJ, Tyrphostin AG 1024 modulates radiosencitivity in human breast cancer cells. Br J Cancer 2001;85(12):2017–2021.
   Google Scholar
• Carapancea M, CosaceanuD, BudiuR, KwiecinskaA, TataranuL, CiubotaruV, AlexandruO, BanitaM, PisoschiC, BäcklundML, LewensohnR, and DricuA, Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells. J Neuro-Oncol 2007;85:245–254.
   PubMed Web of Science ®Google Scholar
• Benini S, ManaraMC, BaldiniN, CerisanoV, SerraM, MercuriM, LolliniPL, NanniP, PicciP, and ScotlandiK, Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001;7:1790–1797.
   PubMed Web of Science ®Google Scholar
• Martins AS, MackintoshC, MartinDH, CamposM, HernandezT, OrdonezJL, and de Alava E, Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with lmatinib, doxorubicin or vincristine is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12(11):3532–3540.
   PubMed Web of Science ®Google Scholar
• Messerschmitt PJ, RettewAN, BrookoverRE, GarciaRM, GettyPJ, and GreenfieldEM, Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 2008;466:2168–2175.
   PubMed Web of Science ®Google Scholar
• Serra M, ScotlandiK, ManaraMC, MauriciD, LolliniPL, de GiovanniC, ToffoliG, and BaldiniN, Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 1993;13:323–330.
   PubMed Web of Science ®Google Scholar
• Hattinger CM, StoicoG, MichelacciF, PaselloM, SciontiI, RemondiniD, CastellaniGC, FanelliM, ScotlandiK, PicciP, and SerraM, Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosome Cancer 2009;48:289–309.
   PubMed Web of Science ®Google Scholar
• Rasband WS. ImageJ. Bethesda, MD: US National Institute of Health, 1997–2008. http://rsb.info.nih.gov/ij/.
   Google Scholar
• Chou TC, Talalay P. Quantitative analysis of does-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
   PubMedGoogle Scholar
• Niyazi M, Niyazi I, Belka C. Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol 2007;2:4.
   PubMed Web of Science ®Google Scholar
• Franken NAP, RodermondHM, StapJ, HavemanJ, and van Bree C, Clonogenic assay of cells in vitro. Nat Protoc 2006;1(5):2315–2319.
   PubMed Web of Science ®Google Scholar
• Bahr C, Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth—novel approaches to the inhibition of IGF-1R function. Growth Factors 2005;23(1):1–14.
   PubMed Web of Science ®Google Scholar
• Baserga R, Peruzzi F, Reiss K. Mini-Review: the IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873–877.
   PubMed Web of Science ®Google Scholar
• von Willebrand M, ZacksenhausE, ChenE, GlazerP, and HalabanR, The Tyrphostin AG1024 accelerates the degradation of phosphorylated forms of retinoblastoma protein (pRb) and restores pRb tumor suppressive function in melanoma cells. Cancer Res 2003;63:1420–1429.
   PubMed Web of Science ®Google Scholar
• Beech DJ, Parekh N, Pang Y. Insulin-like growth factor-I recptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep 2001;8:325–329.
   PubMed Web of Science ®Google Scholar
• Kai K, D'CostaS, SillsRC, and KimY, Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009;278:49–55.
   PubMed Web of Science ®Google Scholar
• Burrow S, AndrulisIL, PollakM, and BellRS, Expression of insulin-like growth factor receptor, IGF-1 and IGF-2 in primary and metastatic osteosarcoma. Eur J Surg Oncol 1998;69:21–27.
   Google Scholar
• Dunn SE, HardmanRA, KariFW, and BarrettJC, Insulin-like growth factor 1 (IGF-1R) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57:2687–2693.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004;108:334–341.
   PubMed Web of Science ®Google Scholar
• Yu D, WatanabeH, ShibuyaH, and MiuraM, Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor. J Biol Chem 2003;278:6702–6709.
   PubMed Web of Science ®Google Scholar
• Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop 2006;30(6):445–451.
   PubMed Web of Science ®Google Scholar
• Wittig JC, BicklesJ, PriebatD, JelinekJ, Kellar-GraneyK, ShmooklerB, and MalawerMM, Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 2002;65(6):1123–1132.
   PubMed Web of Science ®Google Scholar
• Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 2008;8:384–392.
   PubMed Web of Science ®Google Scholar
• Lindsay CR, ChanE, EvansTR, CampbellS, BellP, StephensAW, FrankeA, PoondruS, RothenbergML, and PuzanovI, Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors (2009 ASCO Annual Meeting Proceedings Post-Meeting Edition). J Clin Oncol 2009;27(15S):2559.
   Google Scholar
• Rosenthal SM, Cheng ZQ. Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Nat Acad Sci USA 1995;92:10307–10311.
   Google Scholar
• Dupont J, Karas M, Le Roith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes ceel cycle components. J Biol Chem 2000;275:35893–35901.
   PubMed Web of Science ®Google Scholar
• Coats S, FlanaganWM, NourseJ, and RobertsJM, Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272:877–880.
   PubMed Web of Science ®Google Scholar
• Samani AA, YakarS, Le roithD, and BrodtP, The role of the IGF system in cancer growth and metasis: overview an recent insights. Endocr Rev 2007;28(1):20–47.
   PubMed Web of Science ®Google Scholar
• Tyagi AK, SinghRP, AgarwalC, ChanDCF, and AgarwalR, Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002;8:3512–3519.
   PubMed Web of Science ®Google Scholar
• DiPaola RS. To arrest or not to G2-M cell-cycle arrest. Clin Cancer Res 2002;8:3311–3314.
   PubMed Web of Science ®Google Scholar
• Kisielewska J, Ligeza J, Klein A. The effect of tyrosine kinase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growthof prostate cancer cells (DU145). Folia Histochem Cyto 2008;46(2):185–191.
   PubMed Web of Science ®Google Scholar
• Timofeev O, CizmeciogluO, SetteleF, KempfT, and HoffmannI, Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition*. J Biol Chem 2010;285(22):16978–16990.
   PubMed Web of Science ®Google Scholar
• Hu B, MitraJ, van den HeuvelS, and EndersGH, S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001;21(8):2755–2766.
   PubMed Web of Science ®Google Scholar
• Welch PJ, Wang JY. Coordinated synthesis and degradation of cdc2 in the mammalian cell cycle. Proc Nat Acad Sci USA 1992;89(7):3093–3097.
   PubMed Web of Science ®Google Scholar
• Rajkumar T, Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anti-Cancer Drugs 2008;19:257–265.
   PubMed Web of Science ®Google Scholar
• Yuan X, ZhuX, HuangX, ShengP, HeA, YangZ, DengR, FengG, and LiaoW, Interferon-a enhances sensitivity of human osteosarcoma U2-OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharm Sin 2007;28(11):1835–1841. doi:10.1111/j.1745-7254.2007.00662.x.
   PubMed Web of Science ®Google Scholar
• Diller L, KasselJ, NelsonCE, GrykaMA, LitwakG, GebhardtM, BressacB, OzturkM, BakerSJ, VogelsteinB, and FriendSH, p53 functions as a cell cycle control protein in osetosarcomas. Mol Cell Biol 1990;10(11):5772–5781.
   PubMed Web of Science ®Google Scholar
• Lock RB, Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affection clonogenic survival. Cancer Res 1996;56:4006–4012.
   PubMed Web of Science ®Google Scholar
• Deplanque G, CeralineJ, LapougeG, DufourP, BergeratJP, and Klein-Soyer C, Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation. Biochem Bioph Res Commun 2004;314:1100–1106.
   PubMed Web of Science ®Google Scholar
• Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391–1399.
   PubMed Web of Science ®Google Scholar
• Gokgoz N, WunderJS, MoussesS, EskandarianS, BellRS, and AndrulisIL, Comparison of p53 mutation in patients with localized osteosarcoma and metastatic osteosarcom. Cell 2001;92:2181–2189.
   Google Scholar
• Overholtzer M, RaoPH, FavisR, LuXY, ElowitzMB, BaranyF, LadanyiM, GorlockR, and LevineAJ, The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Nat Acad Sci USA 2003;100:11547–11552.
   PubMed Web of Science ®Google Scholar